ReviewCell biochemistry and biophysics2026
The Intricate Role of Caspase-6 and Death Receptor-6 in Neurodegenerative Diseases.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From glycemic control to neuroprotection: alogliptin as a repurposed candidate for Huntington's disease.Metabolic brain disease · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspase-6 (Casp6) and Death Receptor 6 (DR6) are critical mediators of programmed cell death and axonal degeneration. Casp6 is activated via the cleavage of disease specific key substrates including tau, huntingtin, α-Synuclein, PrpSc and lamin proteins leading to cytoskeletal destabilization, impaired axonal transport, mitochondrial dysfunction, and synaptic loss. DR6 is upstream to Casp6 and it is activated by the N-terminal fragment of amyloid precursor protein (N-APP). DR6 triggers Caspase-6-dependent axonal self-destruction and neuronal apoptosis. This DR6–Casp6 signaling cascade integrates apoptotic and axon degenerative pathways, bridging developmental pruning mechanisms with pathological neurodegeneration. Emerging evidence also implicates DR6 in Wallerian-like axonal degeneration and neuroinflammation via JNK and caspase signaling. The intricate crosstalk between DR6 activation and Casp6 effector function suggests a convergent mechanism underlying neuronal vulnerability and progressive loss in neurodegenerative disorders. Understanding the molecular interplay between DR6 and Casp6 provides valuable insights into early pathogenic events and identifies potential therapeutic targets for halting or reversing neuronal degeneration.
Indexed as
Identifiers
41335291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.